|
WO2009091531A2
(en)
*
|
2008-01-16 |
2009-07-23 |
The General Hospital Corporation |
Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
|
|
ES2584381T3
(es)
|
2010-05-05 |
2016-09-27 |
Prolynx Llc |
Liberación controlada de compuestos activos desde conjugados macromoleculares
|
|
IN2014DN00101A
(https=)
|
2011-06-06 |
2015-05-15 |
Starpharma Pty Ltd |
|
|
CA2848142C
(en)
|
2011-09-07 |
2021-05-18 |
Prolynx Llc |
Hydrogels with biodegradable crosslinking
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
CA2873112A1
(en)
*
|
2012-05-11 |
2013-11-14 |
Alexander Krantz |
Site-specific labeling and targeted delivery of proteins for the treatment of cancer
|
|
EP2925256A4
(en)
*
|
2013-01-22 |
2016-08-17 |
Prolynx Llc |
SEALANTS HAVING CONTROLLED DEGRADATION
|
|
ES2966631T3
(es)
|
2013-06-19 |
2024-04-23 |
Univ California |
Estructuras químicas para el suministro localizado de agentes terapéuticos
|
|
KR20160075665A
(ko)
|
2013-10-22 |
2016-06-29 |
프로린크스 엘엘시 |
소마토스타틴 및 그 유사체의 컨쥬게이트
|
|
KR102442906B1
(ko)
*
|
2013-12-19 |
2022-09-14 |
씨젠 인크. |
표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
|
|
CN106659796B
(zh)
*
|
2014-03-14 |
2021-04-30 |
加利福尼亚大学董事会 |
Tco缀合物和治疗剂递送方法
|
|
CA3007976C
(en)
|
2016-01-08 |
2023-09-26 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
EP3400021A1
(en)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with low npr-c binding
|
|
IL259827B2
(en)
|
2016-01-08 |
2025-07-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
WO2017118700A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with increased nep stability
|
|
DK3400019T3
(da)
|
2016-01-08 |
2022-10-24 |
Ascendis Pharma Growth Disorders As |
CNP-prodrugs med bærerbinding ved ringenheden
|
|
ES3064816T3
(en)
|
2016-01-08 |
2026-04-29 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with reduced side-effects
|
|
MY208384A
(en)
*
|
2016-03-01 |
2025-05-05 |
Ascendis Pharma Bone Diseases As |
Pth prodrugs
|
|
KR20180129825A
(ko)
*
|
2016-03-16 |
2018-12-05 |
프로린크스 엘엘시 |
엑세나타이드 유사체의 연장된 방출 컨쥬게이트
|
|
US11896671B2
(en)
|
2016-07-13 |
2024-02-13 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
US11564974B2
(en)
|
2016-09-29 |
2023-01-31 |
Ascendis Pharma Growth Disorders A/S |
Combination therapy with controlled-release CNP agonists
|
|
HRP20230383T1
(hr)
|
2016-09-29 |
2023-07-07 |
Ascendis Pharma Bone Diseases A/S |
Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
|
|
US12453778B2
(en)
|
2016-09-29 |
2025-10-28 |
Ascendis Pharma Bone Diseases A/S |
Incremental dose finding in controlled-release PTH compounds
|
|
KR102627405B1
(ko)
|
2016-09-29 |
2024-01-18 |
아센디스 파마 본 디지즈 에이/에스 |
조절 방출 pth 화합물을 위한 투여 용법
|
|
TWI773730B
(zh)
|
2017-02-22 |
2022-08-11 |
瑞典商阿斯特捷利康公司 |
治療性樹枝狀聚合物
|
|
AR111190A1
(es)
|
2017-03-22 |
2019-06-12 |
Genentech Inc |
Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
WO2019058374A1
(en)
|
2017-09-19 |
2019-03-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
N-METHYLATED CYCLIC PEPTIDES AND PRODRUGS THEREOF
|
|
US20200323962A1
(en)
*
|
2017-09-19 |
2020-10-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Lipophilic peptide prodrugs
|
|
MX2020007442A
(es)
|
2018-01-12 |
2020-09-14 |
Prolynx Llc |
Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
|
|
EP3765096A1
(en)
|
2018-03-12 |
2021-01-20 |
Boston Scientific Scimed Inc. |
Scavenging methods, and scavenging system for radiocontrast agents
|
|
CN111918665B
(zh)
|
2018-03-28 |
2024-11-26 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
AU2019246390B2
(en)
|
2018-03-28 |
2025-03-27 |
Ascendis Pharma A/S |
Conjugates
|
|
CN112334152A
(zh)
|
2018-05-18 |
2021-02-05 |
阿森迪斯药物骨疾病股份有限公司 |
Pth缀合物的起始剂量
|
|
WO2020014750A1
(en)
|
2018-07-19 |
2020-01-23 |
Starpharma Pty Ltd |
Therapeutic dendrimer
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
WO2020064847A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
EP3856256A1
(en)
|
2018-09-26 |
2021-08-04 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
|
WO2020064844A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Treatment of infections
|
|
TW202027794A
(zh)
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣３多肽之持續遞送
|
|
CA3125488A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
EP3906065B1
(en)
|
2019-01-04 |
2025-04-30 |
Ascendis Pharma Oncology Division A/S |
Prr agonist for use in the treatment of cancer
|
|
PH12021551591A1
(en)
|
2019-01-04 |
2022-04-18 |
Ascendis Pharma Oncology Div A/S |
Conjugates of pattern recognition receptor agonists
|
|
AU2020204785A1
(en)
|
2019-01-04 |
2021-06-03 |
Ascendis Pharma Oncology Division A/S |
Sustained local drug levels for innate immune agonists
|
|
MX2021008708A
(es)
|
2019-02-11 |
2021-09-21 |
Ascendis Pharma Growth Disorders As |
Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
|
|
MY209748A
(en)
|
2019-02-11 |
2025-07-31 |
Ascendis Pharma Bone Diseases As |
Liquid pharmaceutical formulations of pth conjugates
|
|
CN119970617A
(zh)
|
2019-04-05 |
2025-05-13 |
普罗林科斯有限责任公司 |
改良偶联接头
|
|
CN114126638A
(zh)
*
|
2019-04-26 |
2022-03-01 |
普罗林科斯有限责任公司 |
缓慢释放的细胞因子偶联物
|
|
US12527871B2
(en)
|
2019-06-05 |
2026-01-20 |
Boston Scientific Scimed, Inc. |
Click chemistry capturable platinum-based antineoplastic agents
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
AU2020295725A1
(en)
|
2019-06-21 |
2021-12-02 |
Ascendis Pharma Oncology Division A/S |
Anti-CTLA4 conjugates
|
|
WO2020254603A1
(en)
*
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
|
|
TW202114660A
(zh)
|
2019-06-21 |
2021-04-16 |
丹麥商阿仙帝斯製藥公司 |
酪胺酸激酶抑制劑結合物
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
CA3153644A1
(en)
*
|
2019-09-30 |
2021-04-08 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Protein-macromolecule conjugates and methods of use thereof
|
|
MX2022007371A
(es)
|
2020-01-13 |
2022-07-12 |
Ascendis Pharma Bone Diseases As |
Tratamiento del hipoparatiroidismo.
|
|
EP4146281A1
(en)
|
2020-05-04 |
2023-03-15 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
|
KR20230019889A
(ko)
|
2020-06-03 |
2023-02-09 |
아센디스 파마 온콜로지 디비전 에이/에스 |
Il-2 서열 및 이의 용도
|
|
TW202219060A
(zh)
|
2020-08-28 |
2022-05-16 |
丹麥商阿森迪斯腫瘤製藥有限公司 |
醣基化il-2蛋白及其用途
|
|
WO2022064035A1
(en)
|
2020-09-28 |
2022-03-31 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
JP2024514095A
(ja)
|
2021-04-01 |
2024-03-28 |
アセンディス ファーマ エー／エス |
炎症によって誘発される疾患を治療するための長時間作用型成長ホルモンの使用
|
|
IL311539A
(en)
|
2021-09-22 |
2024-05-01 |
Ascendis Pharma Bone Diseases As |
Long-acting pth compound treatments
|
|
US20250017948A1
(en)
*
|
2021-10-19 |
2025-01-16 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
MX2024006698A
(es)
|
2021-12-13 |
2024-06-19 |
Ascendis Pharma Oncology Div A/S |
Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8).
|
|
EP4529454A1
(en)
|
2022-05-23 |
2025-04-02 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
JP2025537527A
(ja)
|
2022-11-02 |
2025-11-18 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
EP4676535A1
(en)
|
2023-03-06 |
2026-01-14 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
JP2026509773A
(ja)
|
2023-03-06 |
2026-03-25 |
アセンディス ファーマ エー／エス |
アルブミン結合性部分を含む薬物化合物
|
|
WO2024184351A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Compounds of drugs with an albumin binding moiety
|
|
AU2024240722A1
(en)
|
2023-03-20 |
2025-09-18 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
CN121175071A
(zh)
|
2023-05-09 |
2025-12-19 |
阿森迪斯药物肿瘤股份有限公司 |
使用il-2缀合物的新型癌症治疗方法
|
|
IL326658A
(en)
|
2023-09-04 |
2026-04-01 |
Ascendis Pharma Bone Diseases As |
PTH treatment in chronic kidney disease
|
|
WO2025208117A1
(en)
*
|
2024-03-29 |
2025-10-02 |
Maha Therapeutics, Inc. |
Cleavable ester compounds and uses thereof
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|